ストックスクリーナーアプリを入手
150.20
0.28%
-0.42
アフターアワーズ：
150.20
前日終値:
$150.62
開ける：
$150.22
24時間の取引高:
1.87M
Relative Volume:
1.09
時価総額：
$285.49B
収益：
$54.66B
当期純損益:
$13.58B
株価収益率:
21.40
EPS:
7.0171
ネットキャッシュフロー:
$16.05B
1週間 パフォーマンス:
+4.42%
1か月 パフォーマンス:
+7.00%
6か月 パフォーマンス:
-1.16%
1年 パフォーマンス:
+14.28%
1日の値動き範囲:
$149.62
$150.90
1週間の範囲:
$142.31
$151.83
52週間の値動き範囲:
$121.57
$170.46
Novartis Ag Adr Stock (NVS) Company Profile
Compare NVS vs LLY, JNJ, ABBV, MRK
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
150.20 | 285.49B | 54.66B | 13.58B | 16.05B | 7.0171 |
LLY
Lilly Eli Co
|
1,240.34 | 1.11T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
253.79 | 611.61B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
282.68 | 499.53B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
143.63 | 354.36B | 65.51B | 8.93B | 14.12B | 3.5532 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-09-10 | アップグレード | HSBC Securities | Reduce → Hold |
| 2026-09-09 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2026-09-09 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2026-03-11 | アップグレード | Argus | Hold → Buy |
| 2026-01-27 | 開始されました | Citigroup | Buy |
| 2026-01-06 | アップグレード | Barclays | Underweight → Equal Weight |
| 2025-12-08 | アップグレード | JP Morgan | Neutral → Overweight |
| 2025-12-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-09-12 | ダウングレード | Goldman | Neutral → Sell |
| 2025-08-08 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2025-02-13 | ダウングレード | UBS | Buy → Neutral |
| 2025-02-12 | 開始されました | Morgan Stanley | Underweight |
| 2025-02-04 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-12-04 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2024-09-11 | ダウングレード | BofA Securities | Buy → Neutral |
| 2024-09-05 | ダウングレード | Goldman | Buy → Neutral |
| 2024-09-03 | ダウングレード | Jefferies | Buy → Hold |
| 2024-07-19 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2024-02-23 | 開始されました | BMO Capital Markets | Market Perform |
| 2024-01-23 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-01-16 | 再開されました | UBS | Buy |
| 2023-12-18 | ダウングレード | HSBC Securities | Buy → Hold |
| 2023-09-25 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-04-26 | アップグレード | Deutsche Bank | Hold → Buy |
| 2023-03-27 | アップグレード | Deutsche Bank | Sell → Hold |
| 2023-01-26 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-12-05 | アップグレード | Stifel | Hold → Buy |
| 2022-09-15 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2022-09-14 | ダウングレード | Berenberg | Buy → Hold |
| 2022-05-09 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2022-01-10 | 再開されました | Citigroup | Buy |
| 2021-12-14 | ダウングレード | Redburn | Buy → Neutral |
| 2021-12-06 | ダウングレード | Exane BNP Paribas | Outperform → Neutral |
| 2021-12-03 | ダウングレード | Bryan Garnier | Buy → Neutral |
| 2021-09-20 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2021-03-22 | 開始されました | Bernstein | Mkt Perform |
| 2021-03-10 | ダウングレード | Argus | Buy → Hold |
| 2021-02-01 | ダウングレード | Cowen | Outperform → Market Perform |
| 2021-01-15 | 開始されました | Deutsche Bank | Buy |
| 2020-09-29 | 開始されました | Berenberg | Buy |
| 2020-09-10 | アップグレード | UBS | Neutral → Buy |
| 2020-09-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-15 | アップグレード | Citigroup | Neutral → Buy |
| 2020-03-10 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2020-02-25 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-04-25 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-04-25 | アップグレード | Liberum | Hold → Buy |
| 2019-04-10 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2019-01-02 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-12-11 | 再開されました | Jefferies | Buy |
| 2018-10-09 | 開始されました | Guggenheim | Neutral |
| 2018-09-10 | アップグレード | BofA/Merrill | Underperform → Buy |
| 2018-05-29 | ダウングレード | HSBC Securities | Buy → Hold |
| 2018-05-25 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-01-25 | 繰り返されました | Leerink Partners | Outperform |
| 2017-12-06 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2017-07-26 | アップグレード | Morgan Stanley | Underweight → Overweight |
| 2017-07-05 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2017-03-09 | 開始されました | Liberum | Buy |
すべてを表示
Novartis Ag Adr (NVS) 最新ニュース
Novartis wins Rhapsido approval as Bank of America keeps CHF 150 target for Novartis stock - ad-hoc-news.de
Novartis AG : RBC is Neutral - www.marketscreener.com
IgA Nephropathy Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences - StreetInsider
Novartis AG Stock (NVS) Moved Up by 3.00% on Oct 15: Drivers Behind the Movement - TradingKey
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AGNVS - PR Newswire
Novartis AG (NOT.F) Analyst Insights, Price Targets & RecommendationsYahoo Finance - Yahoo! Finance Canada
Genentech Wins Judge's OK Of $18M Novartis Award - Law360
Novartis AG (NVS) Stock Up 3.1% but GF Value Says Overvalued -- GF Score: 68/100 - GuruFocus
US biotech company enforces eye treatment award against Novartis - Global Arbitration Review
Why Novartis (NVS) Stock Is Up Today - Quiver Quantitative
Matchpoint Therapeutics Expands Leadership Team with Appointment of John O’Malley, M.D., Ph.D., as Chief Medical Officer - GlobeNewswire Inc.
Law firm probes Novartis over possible securities fraud after trial failure drops shares 14%. - Pluang
Community health takes a village: Screening in the barber’s chair - Novartis
Novartis AG NVSEF Stock Forecast & Price Target - Yahoo! Finance Canada
NOVARTIS AG N (NOT.HA) Q2 FY2026 earnings call transcript - Yahoo Finance
Novartis AG Rises Monday - Moomoo
Swiss Blue-chip Index Starts Week Upbeat; Roche, Novartis Shares Gain - marketscreener.com
Weekly Recap: Abogen mRNA T‑cell engager investment and Rhapsido approval - TradingView
Novartis AG (CEUX:1NOVNm) Stock PDF (Updated: 2026/10/10) - GuruFocus
Cancer Stocks to Consider as Oncology Innovation Accelerates - Zacks Investment Research
Novartis AG (NOVN.VI) income statement - Yahoo Finance UK
NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido - The Globe and Mail
Swiss Market Index Retreats; Novartis Shares Decline - marketscreener.com
NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido - Zacks Investment Research
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AGNVS - PR Newswire
Novartis achieves Tier 1 in the 2026 CCLA Corporate Mental Health Benchmark - Novartis
Novartis wins FDA approval for a form of chronic hives - marketscreener.com
Novartis AG (NOVN) Gets a Buy from Citi - The Globe and Mail
AI companies run virtual drug trials, aim to improve success of human studies - Reuters
Novartis AG (CEUX:1NOVNM) Cyclically Adjusted Price-to-FCF : (As of Oct. 07, 2026) - GuruFocus
US FDA expands use of Novartis drug for chronic skin condition - Reuters
Why Is Novartis Stock Trading Higher Today?Novartis (NYSE:NVS) - Benzinga
Novartis (NVS) Secures FDA Approval for Rhapsido, Expanding Trea - GuruFocus
Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU) - The Manila Times
Novartis Rhapsido® (remibrutinib) receives FDA approval as - GlobeNewswire
Novartis to Present Key Data on Multiple Sclerosis - marketscreener.com
Novartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026 - marketscreener.com
Novartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026 - GlobeNewswire Inc.
Novartis advances multiple sclerosis innovation with - GlobeNewswire
The patient who changed the course of my career - Novartis
Novartis AG (SWX: NOVN): Now September Has Ended, Is It Now Time To Buy? - Stocks Down Under
Novartis Sues Apotex Over Mekinist Copies, Tafinlar Drug Combo - Bloomberg Law News
Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal - Zacks Investment Research
Sironax Named to Fierce Biotech’s “Fierce 15” List of the Most Innovative and Promising Private Biotechs of 2026 - GlobeNewswire Inc.
BofA Expects Higher Q3 Sales From Novartis Amid Strong Key Growth Drivers - Moomoo
Should You Invest in the VanEck Pharmaceutical ETF (PPH)? - Zacks Investment Research
Total non-current liabilities of Novartis AG – BX:NOT - TradingView
NOVARTIS AG N (NOTA.F) Q2 FY2026 earnings call transcript - Yahoo Finance
Agios' Growth Story Hinges on Mitapivat's Commercial Expansion - Zacks Investment Research
Europe Cancer Metabolism Based Therapeutics Market Forecast to 2035 by Modality, Route, Indication, and Therapy Sales | 25.3% CAGR Drives an $8.54 Billion Opportunity - GlobeNewswire Inc.
Novartis Ag Adr (NVS) 財務データ
収益
当期純利益
現金流量
EPS
Novartis Ag Adr (NVS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Marshall Fiona | Officer |
Feb 12 '26 |
Proposed Sale |
161.35 |
30,743 |
4,960,277 |
0 |
| Bulto Carulla Victor | Officer |
Feb 09 '26 |
Proposed Sale |
156.21 |
7,500 |
1,171,576 |
0 |
0.88%
大文字化:
|
ボリューム (24 時間):